Homogeneous, bioluminescent protease assays: Caspase-3 as a model

被引:104
作者
O'Brien, MA
Daily, WJ
Hesselberth, PE
Moravec, RA
Scurria, MA
Klaubert, DH
Bulleit, RF
Wood, KV
机构
[1] Promega Corp, Madison, WI 53711 USA
[2] Promega Biosci Inc, San Luis Obispo, CA USA
关键词
bioluminescent protease assay; homogeneous caspase-3 assay; bioluminescence; high-throughput screening; bioluminescent caspase assay; luciferase;
D O I
10.1177/1087057104271865
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Using caspase-3 as a model, the authors have developed a strategy for highly sensitive, homogeneous protease assays suitable for high-throughput, automated applications. The assay uses peptide-conjugated aminoluciferin as the protease substrate and a firefly luciferase that has been molecularly evolved for increased stability. By combining the proluminescent caspase-3 substrate, Z-DEVD-aminoluciferin, with a stabilized luciferase in a homogeneous format, the authors developed an assay that is significantly faster and more sensitive than fluorescent caspase-3 assays. The assay has a single-step format, in which protease cleavage of the substrate and luciferase oxidation of the aminoluciferin occurs simultaneously. Because these processes are coupled, they rapidly achieve steady state to maintain stable luminescence for several hours. Maximum sensitivity is attained when this steady state occurs; consequently, this coupled-enzyme system results in a very rapid assay. ne homogeneous format inherently removes trace contamination by free aminoluciferin, resulting in extremely low background and yielding exceptionally high signal-to-noise ratios and excellent Z' factors. Another advantage of a luminescent format is that it avoids problems of cell autofluorescence or fluorescence interference that can be associated with synthetic chemical and natural product libraries. This bioluminescent, homogeneous format should be widely applicable to other protease assays.
引用
收藏
页码:137 / 148
页数:12
相关论文
共 25 条
[1]  
Armstrong RC, 1997, J NEUROSCI, V17, P553
[2]   CALCULATION OF INHIBITOR KI AND INHIBITOR TYPE FROM THE CONCENTRATION OF INHIBITOR FOR 50-PERCENT INHIBITION FOR MICHAELIS-MENTEN ENZYMES [J].
BRANDT, RB ;
LAUX, JE ;
YATES, SW .
BIOCHEMICAL MEDICINE AND METABOLIC BIOLOGY, 1987, 37 (03) :344-349
[3]  
CALI JJ, 2003, 9 ANN C EXH SOC BIOM
[4]   One-step cellular caspase-3/7 assay [J].
Carrasco, RA ;
Stamm, NB ;
Patel, BKR .
BIOTECHNIQUES, 2003, 34 (05) :1064-1067
[5]   Inhibition of human caspases by peptide-based and macromolecular inhibitors [J].
Garcia-Calvo, M ;
Peterson, EP ;
Leiting, B ;
Ruel, R ;
Nicholson, DW ;
Thornberry, NA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (49) :32608-32613
[6]   Application of micro arrayed compound screening (μARCS) to identify inhibitors of caspase-3 [J].
Gopalakrishnan, SM ;
Karvinen, J ;
Kofron, JL ;
Burns, DJ ;
Warrior, U .
JOURNAL OF BIOMOLECULAR SCREENING, 2002, 7 (04) :317-323
[7]   Development of novel assays for proteolytic enzymes using rhodarnine-based fluorogenic substrates [J].
Grant, SK ;
Sklar, JG ;
Cummings, RT .
JOURNAL OF BIOMOLECULAR SCREENING, 2002, 7 (06) :531-540
[8]   Fluorometric and colorimetric detection of caspase activity associated with apoptosis [J].
Gurtu, V ;
Kain, SR ;
Zhang, GH .
ANALYTICAL BIOCHEMISTRY, 1997, 251 (01) :98-102
[9]  
Humpal-Winter Jean, 2001, ScientificWorldJournal, V1, P135, DOI 10.1100/tsw.2001.236
[10]   Homogeneous time-resolved fluorescence quenching assay (LANCE) for caspase-3 [J].
Karvinen, J ;
Hurskainen, P ;
Gopalakrishnan, S ;
Burns, D ;
Warrior, U ;
Hemmilä, I .
JOURNAL OF BIOMOLECULAR SCREENING, 2002, 7 (03) :223-231